CV

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care

Retrieved on: 
Monday, October 23, 2023

The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.

Key Points: 
  • The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.
  • While CVDs are the leading cause of death worldwide, early detection is key in saving lives.
  • The two assays are the collaborative effort of Mindray and HyTest, a Mindray company and a prominent global provider of antibodies and antigens.
  • HyTest, renowned for its cardiac biomarker expertise, had its cardiac troponin complex material selected as the international troponin standard by AACC in 2004.

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care

Retrieved on: 
Monday, October 23, 2023

The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.

Key Points: 
  • The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.
  • While CVDs are the leading cause of death worldwide, early detection is key in saving lives.
  • The two assays are the collaborative effort of Mindray and HyTest, a Mindray company and a prominent global provider of antibodies and antigens.
  • HyTest, renowned for its cardiac biomarker expertise, had its cardiac troponin complex material selected as the international troponin standard by AACC in 2004.

Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023

Retrieved on: 
Wednesday, October 18, 2023

DUBLIN, Oct. 18, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 14 abstracts from across its sleep medicine portfolio, including two oral presentations, at the 17th annual World Sleep 2023 Congress, held October 20-25 in Rio de Janeiro, Brazil.

Key Points: 
  • DUBLIN, Oct. 18, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 14 abstracts from across its sleep medicine portfolio, including two oral presentations, at the 17th annual World Sleep 2023 Congress, held October 20-25 in Rio de Janeiro, Brazil.
  • The oral presentations include findings from the real-world TENOR study, which demonstrated individualized dosing strategies for twice-nightly oxybate treatment in narcolepsy.
  • The World Sleep 2023 schedule is available online and outlines all abstracts, posters and oral presentations slated to be shared at the congress.
  • All abstracts are published in a supplemental issue of Sleep Medicine, the official journal of World Sleep Society, two months after the event.

Banco BBVA Argentina S.A. announces dividend payment - Installment 6 of 6

Retrieved on: 
Tuesday, October 17, 2023

Fractions of less than 1 will be settled in Pesos; or

Key Points: 
  • Fractions of less than 1 will be settled in Pesos; or
    (ii)  Cash option: Up to Ps.
  • Payments will be made in kind, except for those shareholders who expressly elect to receive their dividend in cash in Argentine pesos.
  • Notices given by those who are not holders of shares of Banco BBVA Argentina S.A. as of the Cut-Off Date shall be deemed not to have been submitted and shall be null and void.
  • The dividend will be made available through Banco BBVA Argentina S.A. from 10:00 a.m. to 3:00 p.m., at Av.

Make new friends and become a role model: why you should consider volunteering if you're in your 20s or 30s

Retrieved on: 
Tuesday, October 17, 2023

If you’re aged between 25 and 34, you’re part of the age group least likely to take part in volunteering.

Key Points: 
  • If you’re aged between 25 and 34, you’re part of the age group least likely to take part in volunteering.
  • By comparison, 29% of 16-24 year olds volunteered in the same period, and the average for all age groups was 27%.
  • If you’re in this group, you’re likely to be busy establishing your career and relationships, as well as perhaps having and looking after children.
  • Here are five reasons that might lead you to consider helping out at your local library, food bank or youth club.

Why to do it

    • Much of the mental health benefit from volunteering comes from engaging with other people – often people that you wouldn’t ordinarily meet.
    • Friendship: Making friends as an adult can be tricky – especially now many jobs are hybrid or fully remote, meaning you can’t socialise easily with colleagues.
    • Even if friendships only last for the duration of the volunteer activity, this is still beneficial.
    • You can become part of new social networks where information and other resources get shared, such as new job opportunities.
    • Employability: Although volunteering can lead to paid work, this is not the typical pathway outside of specific work-training programmes.

How to do it

    • However, there are ways you can get the benefits of volunteering while taking part in a flexible way that suits your schedule and circumstances.
    • This could be helping out with a beach clean over a weekend, or occasionally marshalling a local parkrun.
    • While we traditionally view volunteering as something that takes place face-to-face, volunteers can carry out tasks through digital technology.

Ashvattha Therapeutics Announces Appointment of Dr. Sakura Minami as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations

Retrieved on: 
Monday, October 9, 2023

REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations.
  • Ms. Thayer has more than 20 years of progressive leadership experience in clinical development operations across various therapeutic areas from Phase 1 through Phase 3.
  • She previously served as Vice President, Head of Clinical Operations at Recode Therapeutics where she established the clinical operations function at the company.
  • Prior to Recode, she led clinical operations at Global Blood Therapeutics (Pfizer), StemCells Inc, FivePrime Therapeutics (Amgen), CV Therapeutics (Gilead), Titan Pharmaceuticals and Becton Dickinson Immunocytometry Systems.

Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics

Retrieved on: 
Thursday, October 5, 2023

The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Biobank.

Key Points: 
  • The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Biobank.
  • Using the Olink Explore platform, researchers measured around 3,000 proteins in more than 54,000 UKB participant samples.
  • The findings illustrate the immense value of proteogenomics in elucidating biological mechanisms, identifying actionable new biomarkers, and accelerating drug development efforts.
  • “These landmark publications are a powerful demonstration of how next-gen proteomics can reveal crucial biological insights not seen with traditional genomics alone.

Smart Eye Introduces AIS CV Alert: Advanced GSR-Compliant Drowsiness Detection for Buses and Trucks

Retrieved on: 
Thursday, October 5, 2023

Smart Eye, the leading developer of Driver Monitoring System (DMS) technology to the automotive industry, today announced the launch of AIS CV (Commercial Vehicle) Alert: a complete hardware and software driver monitoring system tailored for streamlined implementation of advanced drowsiness detection in buses and trucks.

Key Points: 
  • Smart Eye, the leading developer of Driver Monitoring System (DMS) technology to the automotive industry, today announced the launch of AIS CV (Commercial Vehicle) Alert: a complete hardware and software driver monitoring system tailored for streamlined implementation of advanced drowsiness detection in buses and trucks.
  • AIS CV Alert will be unveiled to the public at Smart Eye’s booth at Busworld Europe in Brussels, Belgium, October 7-12.
  • Experience AIS CV Alert firsthand at Busworld Europe in Brussels, Belgium, from October 7th to 12th, by visiting Smart Eye in booth #1149b.
  • For more information about AIS CV Alert and Smart Eye's driver monitoring solutions, please visit https://smarteye.se/solutions/automotive/fleet-and-aftermarket/ .

Aware Unveils Industry’s Most Accurate Risk Assessment Calculator to Secure Enterprises

Retrieved on: 
Thursday, October 5, 2023

Aware, the AI Data Platform for helping enterprises unify collaboration governance, risk, and compliance (GRC), today announced the industry’s most accurate Risk Assessment Calculator.

Key Points: 
  • Aware, the AI Data Platform for helping enterprises unify collaboration governance, risk, and compliance (GRC), today announced the industry’s most accurate Risk Assessment Calculator.
  • The calculator is the latest application designed by Aware to help organizations bolster their risk and compliance posture.
  • The data cited in Aware’s Risk Assessment Calculator is backed by the 2023 Risk Awareness Benchmark report.
  • Click here to receive your free risk assessment and discover how Aware can help you safeguard your company’s most important data.

Biome Analytics Unveils Next-Generation Echo Quality and Patient Monitoring Tool

Retrieved on: 
Wednesday, October 4, 2023

"Biome is dedicated to transforming healthcare through innovative technology solutions," said Matthew Esham, VP of Analytics at Biome. "The release of Biome’s Surveillance Manager is a testament to our commitment to empowering healthcare providers with the advanced data and insight they need to serve more patients, provide better care, and achieve greater margin-- capabilities that drive operational efficiency, improve quality outcomes and enhance patient care."

Key Points: 
  • Biome Analytics, a leading innovator in cardiovascular performance improvement, is excited to announce the immediate availability of the Biome Surveillance Manager™, its advanced Cardiac Ultrasound Management tool.
  • Ensuring adherence to protocols and delivering high-quality results are crucial for the early detection of cardiac diseases, better patient outcomes, and lower costs.
  • Using unique benchmarks, Biome Surveillance Manager monitors previous study comparisons, calculated ejection fractions, and other critical metrics, helping operators improve their quality and reduce variation.
  • "Biome is dedicated to transforming healthcare through innovative technology solutions," said Matthew Esham, VP of Analytics at Biome.